Cardiovascular and Renal Effects of Bromocriptine in Diabetic Patients with Stage 4 Chronic Kidney Disease
Figure 1
24-hour systolic (SBP), diastolic (DBP), and mean arterial (MAP) ambulatory blood pressure in patients treated with bromocriptine (BEC) and placebo (PBO). The 24-hour ABP values are presented for each group at baseline (a), 3 months (b) and 6 months (c). There were no differences between groups at baseline, but, at 3 and 6 months, significant reductions were seen in the BEC group, both during diurnal and nocturnal hours. .